Anika Therapeutics (ANIK) Proxy filing Summary
Anika Therapeutics (ANIK) achieved $112.8 million in 2025 revenue, driven by OA Pain Management, and generated $11.2 million in operating cash flow. The company’s strategic priorities for 2026 include accelerating commercial channel growth and advancing their HA-based pipeline. Key voting matters for shareholders include the election of three Class III Directors, ratification of Deloitte & Touche LLP as independent auditor, and approval of amendments to incentive and stock purchase plans.
Anika Therapeutics (ANIK) 2026 CG Musculoskeletal Conference Summary
Anika Therapeutics (ANIK) presented a summary of their 2026 CG Musculoskeletal Conference, detailing their strategy to accelerate growth through commercial momentum, product pipeline advancement, and operational discipline. The company highlighted its strong financial position, robust product portfolio in OA pain management and regenerative solutions, and upcoming regulatory milestones for Hyalofast and Cingal. Their strategy leverages differentiated hyaluronic acid-based technologies and aims for continued double-digit growth.
Anika Therapeutics (ANIK) AGM 2026 Summary
Anika Therapeutics held its 2026 Annual General Meeting (AGM) where the CEO and board members provided opening remarks and introduced key personnel. Five shareholder proposals were presented for approval, including the election of directors, ratification of Deloitte & Touche LLP as auditor, an advisory vote on executive compensation, and amendments to incentive and employee stock purchase plans. The board unanimously recommended approval for all proposals.
Anika Therapeutics (ANIK) Proxy filing Summary
Anika Therapeutics will present a revised proposal for its 2017 Omnibus Incentive Plan at the June 18, 2026 annual meeting, reducing the requested share reserve increase to 350,000 shares to address dilution concerns raised by Institutional Shareholder Services. The revised plan lowers potential dilution from 29.40% to 24.88% while maintaining strong governance features. The Board unanimously recommends shareholders vote "FOR" the amended plan.
BlackRock Portfolio Management (NASDAQ: ANIK) discloses 4.1% Anika Therapeutics ownership
BlackRock Portfolio Management LLC has filed an amended ownership report for Anika Therapeutics Inc. common stock, disclosing a 4.1% beneficial ownership stake, totaling 544,710 shares. The firm holds sole voting power over 520,622 shares and sole dispositive power over all 544,710 shares. No single client of BlackRock holds more than five percent of Anika's outstanding common stock.
Anika Therapeutics Expands Revolving Credit Facility Agreement
Anika Therapeutics announced it has expanded its revolving credit facility with Bank of America, N.A. The Fifth Amendment establishes a $50 million senior revolving line of credit with a new maturity date of July 10, 2031, and includes an option to increase total commitments to $100 million. This facility is secured by a first-priority lien on most of Anika's assets and features SOFR-based interest and commitment fees linked to its leverage ratio.
Anika to Issue Second Quarter 2026 Financial Results on Wednesday, July 29, 2026
Anika Therapeutics Inc. will release its second-quarter 2026 financial results before the market opens on Wednesday, July 29, 2026. This will be followed by a conference call at 8:30 a.m. ET to discuss the results and business highlights. Investors can access the call via phone or a live audio webcast on Anika's website.
Anika to Issue Second Quarter 2026 Financial Results on Wednesday, July 29, 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) announced it will release its second quarter 2026 financial results before market open on Wednesday, July 29, 2026. This will be followed by a conference call at 8:30 a.m. ET to discuss the results and business highlights. Investors can access the call via phone or live audio webcast on Anika's website.
Anika Therapeutics to issue Q2FY26 results on July 29
Anika Therapeutics, Inc. (NASDAQ: ANIK) is set to release its Q2FY26 financial results before the market opens on Wednesday, July 29, 2026. The company will host a conference call at 8:30 a.m. ET to discuss the results and provide business highlights. Investors can access the call via a toll-free or international number, with a live audio webcast and presentation materials available on the Investor Relations section of Anika's website.
Anika to Issue Second Quarter 2026 Financial Results on Wednesday, July 29, 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) announced it will release its second quarter 2026 financial results before market open on Wednesday, July 29, 2026. A conference call will follow at 8:30 a.m. ET to discuss the results and business highlights. Investors can access the live audio webcast and presentation materials on the company's website.
Anika sets July 29 conference call for second-quarter results
Anika Therapeutics, Inc. (NASDAQ: ANIK) announced it will release its second quarter 2026 financial results before market open on Wednesday, July 29, 2026. Following the release, management will host a conference call at 8:30 a.m. ET to discuss the results and business highlights, accessible via dial-in numbers and a live webcast. An archived replay and presentation materials will be available on the company's investor relations website.
Anika to Issue Second Quarter 2026 Financial Results on Wednesday, July 29, 2026
Anika Therapeutics, Inc. announced it will release its second quarter 2026 financial results before market open on Wednesday, July 29, 2026. A conference call will follow at 8:30 a.m. ET to discuss the results and business highlights, with access details provided for both phone and webcast. The call and accompanying presentation materials will be available on Anika's investor relations website.
Anika Therapeutics (NASDAQ: ANIK) updates $50M revolving credit line terms
Anika Therapeutics (NASDAQ: ANIK) has updated the terms of its $50 million revolving credit line with Bank of America, N.A. through a Fifth Amendment to its Credit Agreement, extending the maturity date to July 10, 2031. The amended agreement allows for an additional $50 million in commitments, potentially increasing the total facility to $100 million, with interest rates based on SOFR plus a margin tied to Anika’s consolidated leverage ratio. The facility is secured by a first priority lien on most of Anika's assets and includes customary financial covenants.
Anika Therapeutics Enters Fifth Amendment To Credit Agreement - SEC Filing
Anika Therapeutics has announced that it has entered into a Fifth Amendment to its Credit Agreement. This information was disclosed in a recent SEC filing. The news was reported by Reuters.
Anika Therapeutics Extends $50M Revolver to 2031 With Bank of America; Upsize Option to $100M
Anika Therapeutics has extended its senior secured revolving credit facility with Bank of America to July 10, 2031, providing $50 million in commitments with an option to increase to $100 million. The agreement aims to enhance the company's liquidity and financial flexibility for operations and strategic initiatives. This information is based on an SEC filing from July 14, 2026.
Anika Therapeutics, Inc. Amends and Extends $50 Million Senior Revolving Credit Facility with Bank Of America, N.A
Anika Therapeutics, Inc. has amended and extended its $50 million senior revolving credit facility with Bank of America, N.A., setting the new maturity date for July 10, 2031. The agreement allows for a potential increase of up to an additional $50 million in commitments, reaching a maximum aggregate of $100 million. The facility's interest rates will be tied to SOFR plus a spread based on the company's consolidated leverage ratio, and it includes customary covenants and a first priority lien on most of Anika Therapeutics' assets.
Price to earnings forward of Anika Therapeutics Inc. – NASDAQ:ANIK
The article focuses on the "Price to earnings forward" financial metric for Anika Therapeutics Inc. (NASDAQ: ANIK). It indicates that the NASDAQ Stock Market shows no current trading activity for the company, as the market is closed. The content primarily lists navigation elements and disclaimers rather than providing detailed financial analysis.
Price to book forward of Anika Therapeutics Inc. – NASDAQ:ANIK
This article focuses on the "Price to book forward" metric for Anika Therapeutics Inc. (NASDAQ: ANIK). It presents financial data for the company across different periods, including value, change, and percentage change. The content appears to be a basic financial data display from TradingView, indicating that specific metrics are available for the company.
Anika Therapeutics, Inc.(NasdaqGS: ANIK) dropped from Russell 2000 Defensive Index
Anika Therapeutics, Inc. (NasdaqGS: ANIK) has been removed from the Russell 2000 Defensive Index, as reported on June 28, 2026. This news comes amidst other recent updates for the company, including its Q1 2026 earnings report, maintained earnings guidance for fiscal year 2026, and board changes at Xilio Therapeutics, Inc., a related entity. Analysts currently hold a "BUY" consensus for ANIK with an average target price of $17.50, suggesting a potential upside of +19.62%.
Anika Therapeutics, Inc. Actuals & Estimates (NASDAQ:ANIK)
This article provides an overview of Anika Therapeutics, Inc. (NASDAQ:ANIK) stock performance, financial actuals, and analyst estimates. It covers details like current stock price, historical highs and lows, market capitalization, earnings reports, revenue, net income, and upcoming earnings dates. The article also includes analysts' future price forecasts and offers insights into the stock's volatility and technical analysis ratings.
ANIK Forecast — Price Target — Prediction for 2027
This article provides an overview of Anika Therapeutics Inc. (ANIK) stock performance, analyst forecasts, and various financial metrics. It includes the current stock price, historical highs and lows, analyst price targets, and details on recent earnings and revenue. The information helps in understanding ANIK's market position and future outlook, though it advises conducting personal research.
Director at Anika Therapeutics (ANIK) receives 10,402 RSU award, holding 58,273 shares
Anika Therapeutics director Richard Stephen was granted 10,402 restricted stock units (RSUs) on June 18, 2026. These RSUs vest in full by the earlier of the 2027 annual shareholder meeting or June 18, 2027. Following this award, Richard Stephen directly holds 58,273 shares of Anika Therapeutics common stock.
Director at Anika Therapeutics (ANIK) receives 10,402 RSUs equity grant
Anika Therapeutics director Joseph H. Capper received an equity grant of 10,402 Restricted Stock Units (RSUs) on June 18, 2026, increasing his direct holdings to 30,805 shares. These RSUs, granted at no cash cost, will vest in full on the earlier of the company's 2027 annual stockholder meeting or June 18, 2027. This grant aligns his compensation with future company performance and represents stock-based compensation rather than a cash transaction.
Anika Therapeutics increases equity plan shares under amended omnibus and ESPP
Anika Therapeutics' board has approved amendments to its 2017 Omnibus Incentive Plan and 2021 Employee Stock Purchase Plan (ESPP), which will increase share reserves, pending stockholder approval at the 2026 Annual Meeting. The 2017 Plan will reserve an additional 350,000 shares, bringing the total to 6,110,000, while the ESPP will increase by 200,000 shares to a total of 400,000. All shares under the revised 2017 Plan may be granted as Incentive Stock Options (ISOs).
[Form 4] Anika Therapeutics, Inc. Insider Trading Activity
Anika Therapeutics director Sheryl L. Conley reported an acquisition of 10,402 restricted stock units (RSUs) of common stock as an equity award in a Form 4 filing. These RSUs vest fully on the earlier of the company's 2027 annual stockholder meeting or June 18, 2027. Following this award, Conley directly holds 52,970 shares of Anika Therapeutics common stock.
Anika Therapeutics (NASDAQ: ANIK) shareholders back equity plans and director slate
Anika Therapeutics shareholders approved changes to its equity compensation plans and elected three Class III directors at its 2026 Annual Meeting. The approved revisions include increasing the common stock reserved under the omnibus incentive plan by 350,000 shares and doubling the share reserve for the 2021 Employee Stock Purchase Plan from 200,000 to 400,000 shares. Shareholders also ratified Deloitte & Touche LLP as the independent auditor and approved executive compensation on an advisory basis.
Director at Anika Therapeutics (NASDAQ: ANIK) receives 10,402 RSU grant
Anika Therapeutics director Gary P. Fischetti was granted 10,402 restricted stock units (RSUs), increasing his direct holdings to 52,015 shares. The RSUs, valued at $0.00 per share, encourage long-term alignment with shareholder interests by vesting fully on the earlier of the company's 2027 annual stockholder meeting or June 18, 2027. This grant is considered a routine compensation practice rather than an open-market purchase.
Anika Therapeutics Inc (ANIK) Financial Health: Profitability & Balance Sheet Analysis
Anika Therapeutics Inc (ANIK) currently holds a strong financial score of 7.95, placing it 52nd out of 203 in the Healthcare Equipment & Supplies industry. The company reported a 13.16% year-over-year increase in its latest quarterly revenue, reaching $29.61M, and a net profit increase of 3.76%. This indicates robust financial health with average operating efficiency.
Anika Therapeutics Inc (ANIK) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for Anika Therapeutics Inc (ANIK) based on its business segments and geographical regions. As of April 6, 2024, the company's revenue is primarily driven by its OEM Channel (57.09%) and Commercial Channel (42.91%). Geographically, the United States accounts for the largest portion of revenue at 62.10%, followed by Europe (19.69%) and other regions (18.21%).
Anika Therapeutics Inc (ANIK) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Anika Therapeutics Inc's (ANIK) dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past five years and indicates no historical data for stock splits. The page also presents current stock performance data, including its market cap and recent price movements.
Anika Therapeutics Inc (ANIK) Valuation: PE, PB & Fair Value Analysis
The article provides a valuation analysis of Anika Therapeutics Inc (ANIK), noting its current valuation score of 8.58, ranking it 83 out of 203 in the Healthcare Equipment & Supplies industry. It highlights the company's P/E ratio of -18.06, which is significantly below its recent high and above its recent low. The article also mentions that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by Anika Therapeutics Inc.
Anika Therapeutics Inc (ANIK) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Anika Therapeutics Inc (ANIK), detailing its current price momentum, support and resistance levels, and indicator readings. The analysis covers various technical indicators like MACD, RSI, and moving averages (MA5 to MA200), concluding with a "Sell" signal based on the combined technical data.
Anika Therapeutics Inc (ANIK) Earnings Forecast: Future EPS & Revenue Growth Estimates
Anika Therapeutics Inc (ANIK) currently has an earnings forecast score of 9.00, placing it 4th in the Healthcare Equipment & Supplies industry. Analysts have a consensus "Strong Buy" rating for ANIK, with an average price target of $16.00. The company's expected revenue for the next quarter is $29.21 million, and analysts anticipate an EPS of -$0.08 for the upcoming quarter.
(ANIK) Movement Within Algorithmic Entry Frameworks
The article analyzes Anika Therapeutics Inc. (NASDAQ: ANIK) through algorithmic entry frameworks, identifying a strong near-term sentiment with a long-term positive bias. It highlights an exceptional 58.3:1 risk-reward setup targeting a 16.6% gain and provides three institutional trading strategies tailored to different risk profiles. The analysis also includes multi-timeframe signal analysis indicating support and resistance levels.
Anika Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Griffin Stephen D.
This document is a statement of changes in beneficial ownership of securities for Officer Griffin Stephen D. at Anika Therapeutics. It is filed as a Form 4, indicating a mandatory disclosure of transactions by company insiders.
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Anika Therapeutics Inc. announced inducement grants of restricted stock units (RSUs) to a newly hired non-executive employee on June 1, 2026. The grant, covering 3,360 shares, was made under the company's 2021 Inducement Plan and was approved by the compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest in three equal installments over three years, contingent on continuous service.
Anika reports inducement grants
Anika Therapeutics, Inc. announced that it granted restricted stock units (RSUs) covering 3,360 shares of common stock to a newly hired non-executive employee on June 1, 2026. This grant was made under the company's 2021 Inducement Plan and was approved by the compensation committee as a material inducement for the employee's acceptance of employment. The RSUs will vest in three equal installments over three years, contingent on continuous service.
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Anika Therapeutics, Inc. announced inducement grants of restricted stock units (RSUs) covering 3,360 shares of common stock to a newly hired non-executive employee on June 1, 2026. These RSUs were granted under the Anika Therapeutics, Inc. 2021 Inducement Plan and vest in three equal installments over three years, serving as a material inducement for the employee's acceptance of employment. This grant aligns with Nasdaq Listing Rule 5635(c)(4) and did not require stockholder approval.
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Anika Therapeutics, Inc. announced inducement grants of restricted stock units (RSUs) covering 3,360 shares of common stock to a newly hired non-executive employee on June 1, 2026. This grant was made under the Anika Therapeutics, Inc. 2021 Inducement Plan and was approved by the compensation committee, serving as a material inducement for the employee's acceptance of employment. The RSUs will vest in three equal installments over three years, contingent on continuous service.
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Anika Therapeutics, Inc. announced the grant of restricted stock units (RSUs) covering 3,360 shares of common stock to a new non-executive employee on June 1, 2026. This grant, made under the Anika Therapeutics, Inc. 2021 Inducement Plan, serves as a material inducement for the employee's acceptance of employment and will vest in three equal annual installments.
Anika Therapeutics grants 3,360 RSUs to new employee as inducement under Nasdaq rules.
Anika Therapeutics has granted 3,360 restricted stock units (RSUs) to a new non-executive employee. This grant, made on June 1, 2026, serves as an inducement for employment under Nasdaq rules and will vest in equal installments over three years, dependent on continuous service. The move is part of Anika's strategy to attract skilled talent for its osteoarthritis pain management and regenerative solutions business.
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Anika Therapeutics, Inc. announced the grant of 3,360 restricted stock units (RSUs) to a new non-executive employee on June 1, 2026. This grant was an inducement for employment, pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan and Nasdaq Listing Rule 5635(c)(4). The RSUs will vest in three equal annual installments, contingent on continuous service.
New Anika hire receives 3,360 stock units as job inducement
Anika Therapeutics (NASDAQ: ANIK) announced it granted 3,360 restricted stock units (RSUs) to a newly hired non-executive employee as a material inducement for employment. The grant, effective June 1, 2026, was made under the 2021 Inducement Plan and Nasdaq Listing Rule 5635(c)(4), vesting in three equal annual installments over three years contingent on continuous service. This compensation event is considered routine, with similar prior grants having minimal stock price impact.
Anika (NASDAQ: ANIK) CEO exercises RSUs, withholds shares to cover tax
Anika Therapeutics President and CEO, Stephen D. Griffin, exercised 12,840 restricted stock units (RSUs) on June 3, 2026, which converted into common shares. The company withheld 3,769 shares to cover tax obligations related to this vesting event. Following these transactions, Mr. Griffin directly holds 49,742 shares of Anika common stock, marking the second of three equal annual installments from a 2024 RSU grant.
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Anika Therapeutics, Inc. announced the grant of restricted stock units (RSUs) covering 3,360 shares to a newly hired non-executive employee on June 1, 2026. This grant was made as a material inducement for employment under the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, and in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest in three equal installments on the first three anniversaries of the grant date, contingent on continuous service.
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Anika Therapeutics Inc. announced inducement grants of restricted stock units (RSUs) to a newly hired non-executive employee. The grant of 3,360 shares of common stock was made under the Anika Therapeutics, Inc. 2021 Inducement Plan and vests in three equal installments over three years, serving as a material inducement for employment. Anika is a global leader in osteoarthritis pain management and regenerative solutions.
Trading Systems Reacting to (ANIK) Volatility
Quantitative Research Desk reports on Anika Therapeutics Inc. (NASDAQ: ANIK) volatility, noting a near-term neutral sentiment amidst mid and long-term strength. The article details institutional trading strategies, including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for the stock. Key findings include a mid-channel oscillation pattern and an exceptional risk-reward profile for a short setup.
Anika Therapeutics invites ESSKA Congress delegates to explore advances in HA-based cartilage repair
Anika Therapeutics is scheduled to participate in the upcoming ESSKA Congress to discuss advancements in cartilage restoration and tendon repair, focusing on their HA-based technology. The company aims to engage with specialists to demonstrate how these innovations are applied in orthopedic settings. This follows their recent launch of the Integrity Implant System at the Shoulder360 conference, where they also offered demo requests for the product.
About Us | Oil & Gas Journal - Anika Therapeutics Inc. - Common Stock (Nasdaq:ANIK) Stock Quote
This page provides a detailed stock quote for Anika Therapeutics Inc. (Nasdaq: ANIK), including its current price, market performance, trading volume, and key financial metrics. It also features a timeline of recent news and earnings reports related to the company, highlighting announcements and investigations, and offers answers to frequently asked questions about its stock. The content is presented by the Oil & Gas Journal, serving as a platform for financial data.
Anika maintains 2026 revenue guidance of $114M-$122.5M while highlighting Integrity growth and Hyalofast FDA response work
Anika Therapeutics reaffirmed its 2026 revenue guidance, projecting between $114 million and $122.5 million. The company emphasized the growth of its Integrity product line and its ongoing efforts in preparing a response to the FDA regarding Hyalofast. This guidance underscores Anika's confidence in its strategic initiatives and product pipeline.
